In this issue of JAMA Surgery, Reitz et al1 report that metformin prescription status was associated with improved 90-day survival and fewer readmissions in a propensity-matched cohort study of more than 5000 patients with diabetes who underwent a major operation in a multicenter, single health care system over a 5-year period. The study results show that preoperative metformin use was associated with lower adjusted hazard ratios of postoperative mortality and readmission. This study demonstrates how variables besides coexisting medical diseases can affect surgical outcomes. Metformin now joins β-blockers, statins, and immunonutrition as preoperative agents associated with improved surgical outcomes. It may be only a matter of time before optimization of postoperative outcomes with perioperative medications and supplements becomes a standard. To answer this question more completely, further analysis or future trials should factor in statin use, as well as whether medications are continued in the postoperative period.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
George EL, Wren SM. Improving Outcomes After Surgery—An Old Medication With Unexpected Benefits. JAMA Surg. 2020;155(6):e200417. doi:10.1001/jamasurg.2020.0417
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: